Skip to main content
. 2017 Apr 18;8(26):42510–42524. doi: 10.18632/oncotarget.17207

Graphical Abstract: Discovery of Eg5 inhibitor YL001 as a novel antitumor agent.

Graphical Abstract: Discovery of Eg5 inhibitor YL001 as a novel antitumor agent

Left, two rounds of virtual screening results in the discovery of YL001 as an Eg5 inhibitor which can lead to monopolar spindle phenotype. Right, YL001 exhibits potent antitumor activity in the B16 xenograft mouse model.